Member Info for JPP8788

Change of Syms address. Previous correspondence address looked to be his home address. Its now back at Cheapside.. For whatever reason ;)

No, sorry, theres not.

My guess would be a relist of 150m mcap and 2 of accustem to begin with

A lot of talk on twitter and Telegram that okyo itself may be the vehicle to Accustem.

I'm not so sure personally but it makes sense in some ways!

OKYOs current non executive director, John Brancaccio, has just joined the board over at TILS... Meaning we now have Shailubhai, Simon and Brancaccio from TILS... And Cerrone as major shareholder through Panetta.

Looks like StemPrintER/Accustem could be merging here?

Low mcap. Low free float.

At what point is the snapshot relevant? At 8.01am and 4.29 on the record date id expect those two snapshots to look very different...

What cerrone said was that at the record date TILS holders will get an equal amount of shares in the newco. That doesn't necessarily mean an equal percentage.

They would be consolidated to come into line with the shares in issue with Accustem (whatever they may be)

12 billion shares at 0.0023p before suspension will just end up going 10000/1 or something similar. My 30 million shares in BOU will end up as 3000 shares at £2.30 and the equity (£2.8 on suspension) will be factored into the equity split..

Either that or the shares will be cancelled entirely and existing BOU holders will get their share of BOU's share of Accustem... I e. If you're a 0.5% holder of BOU.. You'll get 0.5% of any equity split (probably around 5) of Accustem.

So, this has just taken me from 95% confident of Bould Opportunities being the vehicle for listing Accustem ... To 100%...

In June 2017, Cerrone bought just under 30% of a failing AIM listed company, West African Minerals Ltd. A month later, Kunwar Shalubhai joined the board... The Willy Simon had already been a chairman at WAML for some time..

Six months later, Dec 2017, the company announced they were winding up the business and cancelling shares on AIM, along with the following RNS:

‘the Board intends to seek acquisition opportunities in the life sciences and biotechnology sector. The Board's current intention is that on completion of an acquisition in this new sector, the Board will seek admission of the Company's issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange and to simultaneously cancel trading of its issues share capital on AIM.’

Sounds familiar, right? Take a look at BOU's most recent RNSs.. Almost word for word identical.

Well - that company was then wound up in Jan 2018 renamed Okyo Pharma Limited in Feb 2018, and relisted on the London Main Market in November 2018 as Okyo Pharma Corp in Nov 2018.

The company now holds a patent portfolio of treatment for eye related illnesses and diseases,and Shalubhai and Simon remain on the board.

The people above is FULLY replicable with Accustem and Bould - except there's no need for the delay or costs in winding up the existing business.. And relisting via main market is likely to be much quicker.

Domain names accustem.com and accustemsciences.com are already registered and have been for a month.

Feel free to take a look at the history of WAML and journey to Okyo since - you'll see quite a few similarities with the journey that BOU holders are currently on.

That's it from me - if Accustem doesn't list on the London main market via BOU then slap me across the face with a kipper.

So, this has just taken me from 95% confident of Accustem being our target...

In June 2017, Cerrone bought just under 30% of a failing AIM listed company, West African Minerals Ltd. A month later, Kunwar Shalubhai joined the board... The Willy Simon had already been a chairman at WAML for some time..

Six months later, Dec 2017, the company announced they were winding up the business and cancelling shares on AIM, along with the following RNS:

‘the Board intends to seek acquisition opportunities in the life sciences and biotechnology sector. The Board's current intention is that on completion of an acquisition in this new sector, the Board will seek admission of the Company's issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange and to simultaneously cancel trading of its issues share capital on AIM.’

Sounds familiar, right?

Well - that company was then wound up in Jan 2018 renamed Okyo Pharma Limited in Feb 2018, and relisted on the London Main Market in November 2018 as Okyo Pharma Corp in Nov 2018.

The company now holds a patent portfolio of treatment for eye related illnesses and diseases.

The people above is FULLY replicable with Accustem and Bould - except there's no need for the delay or costs in winding up the existing business.. And relisting via main market is likely to be much quicker.

Domain names accustem.com and accustemsciences.com are already registered and have been for a month.

Feel free to take a look at the history of WAML and journey to Okyo since - you'll see quite a few similarities with the journey that we're currently on.

That's it from me - if Accustem doesn't list on the London main market via BOU then slap me across the face with a kipper.

"required prospectus".. Interesting. Very specific wording that.

Cerrone said at the TILS AGM that the "a circular" will be sent to investors in 14 days.

Sounds viable.

Ridiculous mcap - 2m

Decent order book.. Cash in the bank.. Proven business model.. Last business update wasn't that bad!

Buy and hold for 6 months.

ICF are advisories of Midatech Pharma.

Just to clarify... The AGM doesn't contain any resolutions related to Accustem.

The company announced last week "that plans to effect the demerger of StemPrintER from the Group are continuing to be progressed and it is now expected that a circular will now be sent to shareholders shortly after the Annual General Meeting to be held on 16 July 2020"

So maybe later on Thursday/Friday best case scenario.

None of the other 3 drugs have the NDA stage on their progress table either...

This could be a big discovery.

Just as a side note.. I've just found out that TILS was a double RTO

Alexander David Investments into Tiziana Pharma Ltd in 2013 and then into Tiziana Life Sciences PLC...

Quite clear that Cerrone likes to get things done via RTO for a quicker, cheaper market listing.

Appreciate that countingcards... If you have any success with your research please do share.

Another nice bit of information found on Allan Syms LinkedIn..

"Sector Specialist: Life Sciences China and USA
UKTI
May 2010 - Mar 2013
Sector specialist in life sciences developing trade and investment opportunities in China and USA.

I remain an independent consultant, advisor and non-executive to high technology life science businesses in the UK and SE Asia."

So AS was a"sector specialist" in life sciences up to the point that StemPrintER was in it's infancy... And he remains a consultant/advisor to high tech life science companies since then...

I think a rough ballpark figure is that we get 5% of the company and upon listing it goes from 50 million to 150 million within a few weeks.

That would give us approx 2.5x returns on pre suspension prices.

The 5% is maybe a little bit blue-sky thinking. But you have to be able to attribute some significant value to BOU being able to list Accustem within days/weeks of the EGM (rather that a 6 month IPO), with limited costs, with some cash in the coffers of Bould, and with Syms having some extremely useful connections and experience in the metastasis/oncology field.

This will be a fantastic earner for all of us. Should you choose to ride it out until Accustem is bought out then I wouldn't expect 10x returns from pre-suspension levels...

Hi asaynor.. Sorry I don't know what sort of equity spilt was involved when TILS rto'd into Alexander David Investments... And I don't think it has any relevance here.

The value in Accustem is very likely to be in the 3-6 months after listing (when a takeover will become more and more likely). Initial listing may well be in the 100-150 mil range.. And if BOU holders only get a few percent then we could be left feeling a little short changed.

But a large pharma is likely to come sniffing. And that's where the profit will be.

Considering Tiziana themselves were listen in 2013 via a cash shell (Alexander David Investments plc) then I think a listing via a RTO is likely. I do however think that it will be Bould Opportunities that are used as the vehicle to list Accustem...

The share a similar registered office (Cheapside London)

Bould CEO Syms has previous experience with spin outs

Syms completed a PhD in Cancer Research at Cardiff University.. Tiziana was founded originally by a group of 3 scientists at that same University... Cerrone was part funder of the original study..

Syms was a speaker at BioMotif in Cardiff in 2013 (about the same time Tiziana was founded)

There's plenty of other links soo if you're prepared to dig long enough and hard enough....

A little more of my own research here to keep you all amused...

If you go back around 7 years, Tiziana Life Sciences was formed originally by a team of three - Brancale, Clarkson and Westwell... Cerrone himself part funded the research into metastasis specifically.

This was done a few years after GC lost his wife to breast cancer.. And has been interviewed many times saying that he wants to make a difference to other victims lifespan.

Cerrone then listed TILS on AIM around a year later, RTOing into a cash shell previously known as "Alexander David Investments plc", and subsequently bought out the three other directors a few years afterwards.

So why is this all important? Well.. I guess the fact TILS were formed from a cash shell is of significant interest.. But actually... Let's look back to the start... Cardiff University.. Where it all began..

Is there a connection between the city of Cardiff (and the university itself) and our CEO, Allan Syms? I'll leave the answer to find out for yourselves.. But the fact that Syms completed a PhD in Cancer Research at Cardiff University.. And the fact that Syms other venture, MyPinPad, is also listed in Cardiff... There are other links too... You just have to find them.

Join the dots people...